Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1601 to 1650 of 3761 results for treatment

  1. Deep brain stimulation for refractory chronic pain syndromes (excluding headache) (HTG253)

    Evidence-based recommendations on deep brain stimulation for refractory chronic pain syndromes (excluding headache). This involves stimulating a precise area of the brain using an electrode to treat the chronic pain.

  2. Percutaneous radiofrequency ablation for primary or secondary lung cancers (HTG244)

    Evidence-based recommendations on percutaneous radiofrequency ablation for primary or secondary lung cancers. This involves inserting 1 or more electrodes (needle-like probes) through the chest into the lung and using an electrical current to produce heat to destroy the cancer cells.

  3. Coil embolisation of unruptured intracranial aneurysms (HTG63)

    Evidence-based recommendations on coil embolisation of unruptured intracranial aneurysms. This involves placing coils inside the aneurysm using a thin tube to make the blood clot so it is less likely to burst.

  4. Artificial Intelligence assisted echocardiography to support diagnosis of heart failure: Early Value Assessment

    In development Reference number: GID-HTE10067 Expected publication date:  20 May 2026

  5. Irreversible electroporation for treating renal cancer (HTG303)

    Evidence-based recommendations on irreversible electroporation (IRE) for treating renal cancer. This involves using electrical pulses to kill cancer cells, applied directly to the tumour through special needles.

  6. Thrombin injections for pseudoaneurysms (HTG33)

    Evidence-based recommendations on thrombin injections for pseudoaneurysms. This involves injecting thrombin into the pseudoaneurysm. The aim is to form a small clot to plug the ‘hole’ in the artery.

  7. Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism (HTG705)

    Evidence-based recommendations on percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism. This involves removing the clot through a catheter inserted into a vein.

  8. Neuropathic pain relief:- Does early treatment with a centrally acting analgesic (for example pregabalin) reduce the frequency or severity of neuropathic pain in people with spinal cord injury?

    ID NG41/1 Question Neuropathic pain relief:- Does early treatment with a centrally acting analgesic (for example pregabalin) reduce the...

  9. Ultrasound-guided percutaneous radiofrequency ablation for benign thyroid nodules (HTG416)

    Evidence-based recommendations on ultrasound-guided percutaneous radiofrequency ablation for treating benign thyroid nodules in adults. This involves using heat energy to destroy tissue in the nodules.

  10. Trabeculotomy ab interno for open angle glaucoma (HTG264)

    Evidence-based recommendations on trabeculotomy ab interno for open angle glaucoma. This involves using a specifically designed surgical instrument to remove a portion of tissue, with the aim of improving the eye’s drainage pathway.

  11. Epilepsy: register (IND253)

    This indicator covers the contractor establishing and maintaining a register of patients aged 18 or over receiving drug treatment for epilepsy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM237

  12. Transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia in adults (HTG493)

    Evidence-based recommendations on transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia in adults. This involves electrically stimulating nerves in the throat or neck, while the person swallows. The aim is to strengthen the muscles involved in swallowing.

  13. Preoperative high dose rate brachytherapy for rectal cancer (HTG383)

    Evidence-based recommendations on preoperative high dose rate brachytherapy for rectal cancers. This involves inserting an applicator into the rectum and using it to deliver radiation to the tumour.

  14. Percutaneous transluminal renal sympathetic denervation for resistant hypertension (HTG662)

    Evidence-based recommendations on percutaneous transluminal renal sympathetic denervation for resistant hypertension. This involves inserting a device through the skin (percutaneous) into an artery in the thigh and then into the renal arteries (transluminal). It sends radio or sound waves to destroy the nerves in the renal arteries (sympathetic denervation). The aim is to lower blood pressure.

  15. Selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver (HTG720)

    Evidence-based recommendations on selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver. This involves injecting tiny radioactive spheres into the blood vessels that supply the liver metastases.

  16. High-intensity focused ultrasound for symptomatic breast fibroadenoma (HTG449)

    Evidence-based recommendations on high-intensity focused ultrasound for symptomatic breast fibroadenoma in adults. This involves using high-frequency sound waves to heat up the tissues in the lump.

  17. SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea (HTG598)

    Evidence-based recommendations on SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea.

  18. Drug allergy: diagnosis and management (CG183)

    This guideline covers diagnosing and managing drug allergy in all age groups. It aims to make it easier for professionals to tell when someone is having an allergic reaction, by specifying the key signs and patterns to look out for. It also makes recommendations on improving people’s understanding of their drug allergies, and ensuring these are recorded properly in their medical records.

  19. Cryotherapy for chronic rhinitis (HTG692)

    Evidence-based recommendations on cryotherapy for chronic rhinitis. This involves destroying a nerve in the nose to reduce chronic rhinitis symptoms.

  20. Gynaecological conditions: rates of hysterectomy (heavy menstrual bleeding) (IND58)

    This indicator covers rates of hysterectomy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG77

  21. Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessment

    In development Reference number: GID-HTE10065 Expected publication date:  02 April 2026

  22. moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment (HTG257)

    Evidence-based recommendations on moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment.

  23. Frequency and duration of endoscopic follow-up: What is the optimal frequency and duration of endoscopic follow-up for patients who have received endoscopic treatment for Barrett's oesophagus with dysplasia?

    duration of endoscopic follow-up for patients who have received endoscopic treatment for Barrett's oesophagus with dysplasia? Any...

  24. Endoscopic ablation for an anal fistula (HTG506)

    Evidence-based recommendations on endoscopic ablation for an anal fistula in adults. This involves applying heat to the fistula.

  25. Radical treatment of squamous cell carcinoma of the oesophagus:- Does the addition of surgery to chemoradiotherapy improve disease-free and overall survival inpeople with squamous cell carcinoma of the oesophagus?

    Recommendation ID NG83/1 Question Radical treatment of squamous cell carcinoma of the oesophagus:- Does the addition of surgery to...

  26. Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation (HTG752)

    Evidence-based recommendations on transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation. This involves implanting a replacement valve inside the faulty native valve.

  27. What is the clinical and cost effectiveness, post treatment and at longer-term follow‑up, of behavioural activation compared with other psychological therapies in children aged 5 to 11 years and young people aged 12 to 18 years with mild or moderate to severe depression?

    Question What is the clinical and cost effectiveness, post treatment and at longer-term follow‑up, of behavioural activation compared...

  28. Liposuction for chronic lymphoedema (HTG622)

    Evidence-based recommendations on liposuction for chronic lymphoedema in adults. This involves using suction to remove fluid and fat through punctures in the skin.

  29. Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (HTG305)

    Evidence-based recommendations on electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma. This involves applying short, powerful pulses of electricity to the tumour, allowing an anticancer drug to pass through into the cells.

  30. Selective internal radiation therapy for unresectable colorectal metastases in the liver (HTG542)

    Evidence-based recommendations on selective internal radiation therapy for unresectable colorectal metastases in the liver in adults. This involves injecting beads that emit radiation directly into the tumour.

  31. Injectable bulking agents for faecal incontinence (HTG135)

    Evidence-based recommendations on injectable bulking agents for faecal incontinence. This involves injecting a material into the muscles around the anus to bulk the sides of the sphincter.

  32. Liposuction for chronic lipoedema (HTG618)

    Evidence-based recommendations on liposuction for chronic lipoedema in adults. This involves using suction to remove abnormal fat.

  33. CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack (HTG724)

    Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack.

  34. Extracorporeal shockwave therapy for refractory plantar fasciitis (HTG200)

    Evidence-based recommendations on extracorporeal shockwave therapy for refractory plantar fasciitis. This involves using a machine to deliver sound waves to the painful area, with the aim to stimulate healing of the fascia.

  35. NICE real-world evidence framework (ECD9)

    This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence

  36. How voluntary and community sector organisations can help us develop guidance

    How voluntary and community sector (VCS) organisations can help NICE develop guidance

  37. How voluntary and community sector organisations can help us develop guidance

    How voluntary and community sector (VCS) organisations can help NICE develop guidance

  38. Palliative photodynamic therapy for advanced oesophageal cancer (HTG132)

    Evidence-based recommendations on palliative photodynamic therapy for treating advanced oesophageal cancer. This involves injecting a photosensitising agent into the tumour and using light to activate it and destroy the tumour cells.

  39. Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212]

    In development Reference number: GID-TA11203 Expected publication date:  08 April 2026

  40. Photodynamic therapy for early-stage oesophageal cancer (HTG128)

    Evidence-based recommendations on photodynamic therapy for early-stage oesophageal cancer. This involves injecting a photosensitising agent into the tumour which is then activated by a light to destroy the tumour cells.

  41. Transvaginal laser therapy for urogenital atrophy (HTG582)

    Evidence-based recommendations on transvaginal laser therapy for urogenital atrophy. This involves using a laser in the vagina to increase its strength and elasticity, to improve symptoms of urogenital atrophy.

  42. Endoscopic radiofrequency therapy of the anal sphincter for faecal incontinence (HTG262)

    Evidence-based recommendations on endoscopic radiofrequency therapy of the anal sphincter for faecal incontinence. This involves applying radiofrequency energy to the anal wall, with the aim of inducing muscle changes to improve muscle tone and help control bowel movement.

  43. Frequency and duration of endoscopic follow-up: What is the optimal frequency and duration of endoscopic follow-up for patients who have received endoscopic treatment for stage 1 oesophageal adenocarcinoma?

    duration of endoscopic follow-up for patients who have received endoscopic treatment for stage 1 oesophageal adenocarcinoma? Any...

  44. Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia (HTG698)

    Evidence-based recommendations on percutaneous deep venous arterialisation for chronic limb-threatening ischaemia. This involves making a hole between a blocked artery and a vein, allowing the blood to flow into the leg beyond the blockage.

  45. Epiduroscopic lumbar discectomy through the sacral hiatus for sciatica (HTG425)

    Evidence-based recommendations on epiduroscopic lumbar discectomy through the sacral hiatus for sciatica in adults. This involves removing the part of the spinal disc pressing against the spinal nerve, to relieve pain.

  46. Percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid nodules (HTG646)

    Evidence-based recommendations on percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid nodules. This involves using microwaves from a wire inserted into the nodule to heat and destroy it (ablation).